Advanced Micro Devices (NASDAQ: AMD) has successfully transformed itself over the past five years into a formidable player in the CPU market. You only have to look at AMD's gross margin to see how far the company has come. In the third quarter of 2017, AMD managed an adjusted gross margin of just 35%. Read More...
Motley Fool
Why TG Therapeutics Stock Was a Solid Winner This Week
On Wednesday, TG Therapeutics divulged the happy news that it earned Food and Drug Administration (FDA) approval for multiple sclerosis (MS) drug ublituximab-xiiy, brand-named Briumvi. The approval covers the treatment of relapsing forms of MS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. In its press release on the FDA’s nod, TG Therapeutics quoted its CEO Michael Weiss as saying that “We believe in the importance of treatment alternatives for patients and believe the profile of Briumvi offers unique attributes to patients and physicians alike.”
